Health Care [ 11/12 ] | Biotechnology [ 67/74 ]
NASDAQ | Common Stock
Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally.
It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant.
The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies.
In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract t; and AGEN1884.
The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks.
It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme.
The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011.
Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 12, 25 | -2.04 Decreased by -1.47 K% | -2.54 Increased by +19.75% |
| Nov 5, 24 | -3.08 Decreased by -1.82 K% | -2.33 Decreased by -32.19% |
| Aug 8, 24 | -2.52 Decreased by -1.16 K% | -1.44 Decreased by -75.00% |
| May 7, 24 | -3.04 Decreased by -1.28 K% | -3.22 Increased by +5.59% |
| Mar 14, 24 | -0.13 Increased by +45.83% | -0.05 Decreased by -160.00% |
| Nov 7, 23 | -0.16 Increased by +15.79% | -0.19 Increased by +15.79% |
| Aug 8, 23 | -0.20 Decreased by -17.65% | -0.20 |
| May 9, 23 | -0.22 Decreased by -15.79% | -0.21 Decreased by -4.76% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 26.84 M Decreased by -67.98% | -45.86 M Increased by +0.93% | Decreased by -170.88% Decreased by -209.35% |
| Sep 30, 24 | 25.11 M Increased by +3.28% | -66.39 M Decreased by -6.73% | Decreased by -264.36% Decreased by -3.34% |
| Jun 30, 24 | 23.51 M Decreased by -7.06% | -53.08 M Increased by +27.71% | Decreased by -225.79% Increased by +22.22% |
| Mar 31, 24 | 28.00 M Increased by +22.28% | -61.89 M Increased by +9.33% | Decreased by -220.98% Increased by +25.85% |
| Dec 31, 23 | 83.80 M Increased by +195.22% | -46.29 M Increased by +52.47% | Decreased by -55.24% Increased by +83.90% |
| Sep 30, 23 | 24.31 M Increased by +6.77% | -62.20 M Increased by +16.26% | Decreased by -255.82% Increased by +21.57% |
| Jun 30, 23 | 25.30 M Increased by +20.88% | -73.43 M Decreased by -43.69% | Decreased by -290.28% Decreased by -18.86% |
| Mar 31, 23 | 22.90 M Decreased by -11.72% | -68.25 M Decreased by -7.54% | Decreased by -298.03% Decreased by -21.81% |